Songming Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Songming Chen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Chujuan Zeng
Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
2 shared publicationsD. M. Wang
Department of Cardiology, The First Affiliated Hospital, Medical College, Shantou University, Shantou Guangdong, China
1 shared publicationHailin Liang
Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College of Shantou City, Shantou, China
1 shared publicationHanfei Lin
Department of Nephrology and
1 shared publication- Heng Wee Tan
The Second Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
1 shared publication Jia-Wei Zhang
Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47632
Triglyceride-glucose index demonstrates false-positive association with cardiometabolic multimorbidity progression in cardiometabolic disease patients: Observation and Mendelian randomization study
The Triglyceride-Glucose (TyG) index is a recognized predictor for incident cardiometabolic diseases (CMDs) and cardiometabolic multimorbidity (CMM) in general populations. However, its utility for predicting progression from single CMD to CMM among patients with existing CMD remains unverified. This study combined retrospective cohort analyses (cross-sectional cohorts: China Health and Retirement Longitudinal Study [CHARLS]-1, n = 5415; First Affiliated Hospital of Shantou University Medical Center, n = 544; longitudinal cohort: CHARLS-2, n = 1866) with Mendelian randomization to evaluate this relationship. Cross-sectional analyses initially indicated positive associations between elevated TyG index and CMM progression (per-standard deviation increase: CHARLS-1 adjusted odds ratio [OR] = 1.43, 95% confidence interval [CI]: 1.30–1.57; First Affiliated Hospital of Shantou University Medical Center adjusted OR = 1.75, 95% CI: 1.33–2.31). However, longitudinal analysis showed no significant association after multivariable adjustment (hazard ratio = 0.87, 95% CI: 0.73–1.02). Crucially, Mendelian randomization analysis with sequential exclusion of confounder-associated single nucleotide polymorphisms (glucose, triglycerides, and body mass index) revealed no causal relationship (Model 3 inverse-variance weighted OR = 0.647, 95% CI: 0.412–1.014). These findings demonstrate that the apparent association between TyG index and CMM progression in patients with baseline CMD is likely a false-positive result attributable to residual confounding, with no causal link supported by rigorous longitudinal or genetic evidence. Thus, while TyG is valuable for predicting initial CMD onset, it lacks clinical utility for forecasting progression to multimorbidity in established patients, necessitating exploration of alternative biomarkers for this critical transition.
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47632
Open AccessTriglyceride-glucose index demonstrates false-positive association with cardiometabolic multimorbidity progression in cardiometabolic disease patients: Observation and Mendelian randomization study
The Triglyceride-Glucose (TyG) index is a recognized predictor for incident cardiometabolic diseases (CMDs) and cardiometabolic multimorbidity (CMM) in general populations. However, its utility for predicting progression from single CMD to CMM among patients with existing CMD remains unverified. This study combined retrospective cohort analyses (cross-sectional cohorts: China Health and Retirement Longitudinal Study [CHARLS]-1, n = 5415; First Affiliated Hospital of Shantou University Medical Center, n = 544; longitudinal cohort: CHARLS-2, n = 1866) with Mendelian randomization to evaluate this relationship. Cross-sectional analyses initially indicated positive associations between elevated TyG index and CMM progression (per-standard deviation increase: CHARLS-1 adjusted odds ratio [OR] = 1.43, 95% confidence interval [CI]: 1.30–1.57; First Affiliated Hospital of Shantou University Medical Center adjusted OR = 1.75, 95% CI: 1.33–2.31). However, longitudinal analysis showed no significant association after multivariable adjustment (hazard ratio = 0.87, 95% CI: 0.73–1.02). Crucially, Mendelian randomization analysis with sequential exclusion of confounder-associated single nucleotide polymorphisms (glucose, triglycerides, and body mass index) revealed no causal relationship (Model 3 inverse-variance weighted OR = 0.647, 95% CI: 0.412–1.014). These findings demonstrate that the apparent association between TyG index and CMM progression in patients with baseline CMD is likely a false-positive result attributable to residual confounding, with no causal link supported by rigorous longitudinal or genetic evidence. Thus, while TyG is valuable for predicting initial CMD onset, it lacks clinical utility for forecasting progression to multimorbidity in established patients, necessitating exploration of alternative biomarkers for this critical transition.
- Open Access
- 16 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 867
Association between stress hyperglycemia ratio and all-cause mortality in patients with coronary heart disease
Stress hyperglycemia ratio (SHR) has been associated with adverse clinical outcomes in hospitalized patients with acute coronary syndromes (ACS). However,
- 16 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 867
Open AccessAssociation between stress hyperglycemia ratio and all-cause mortality in patients with coronary heart disease
Stress hyperglycemia ratio (SHR) has been associated with adverse clinical outcomes in hospitalized patients with acute coronary syndromes (ACS). However,
- 1 December 2018
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 356 (6) , 576-577
Effect of Trimetazidine on Preventing Cotrast-Induced Acute Kidney Injury in Patients With Diabetes
- 1 December 2018
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 356 (6) , 576-577
Effect of Trimetazidine on Preventing Cotrast-Induced Acute Kidney Injury in Patients With Diabetes
- 24 March 2017
- Published by Springer Nature in Sleep and Breathing
- Vol. 21 (4) , 963-964
Effect of rhythm control on sleep disordered breathing in patients with atrial fibrillation or flutter: a systematic review and meta-analysis
- 24 March 2017
- Published by Springer Nature in Sleep and Breathing
- Vol. 21 (4) , 963-964
Effect of rhythm control on sleep disordered breathing in patients with atrial fibrillation or flutter: a systematic review and meta-analysis
- Open Access
- 1 April 2005
- Published by Wiley in Clinical Cardiology
- Vol. 28 (4) , 197-201
Study on changes of heme oxygenase‐1 expression in patients with coronary heart disease
Background: Heme oxygenase (HO) is a rate‐limiting enzyme of endogenetic carbon monoxide (CO) that degrades heme into carbon monoxide, bilirubin, and iron. These products have important physiologic effects: bilirubin is a potent antioxidant that can act against ischemia/reperfusion injury; there is a negative correlation between the content of HO‐1 and the incidence of coronary heart disease (CHD). Hypothesis: This study was undertaken to investigate the changes of HO‐1 in patients with CHD. Methods: Thirty‐five patients with acute myocardial infarction (AMI), 40 patients with unstable angina pectoris (UAP, diagnosed by coronary angiography), and 30 patients with stable angina pectoris (AP, diagnosed by coronary angiography) were selected for the study; another 30 patients with normal coronary artery (diagnosed by coronary angiography) were selected as controls. The levels of HO‐1 protein expression in monocyte and lymphocyte in the subjects were tested by immunohistochemistry and western blot. Computer picture analyzing systems were also used to measure the levels of HO‐1 protein expression. Results: Heme oxygenase‐1 protein is located in cell plasma. The levels of HO‐1 protein expression in patients with CHD were significantly higher than in those without CHD (pConclusions: There is a higher expression of HO‐1 in patients with CHD. The levels of HO‐1 protein are associated with the severity of CHD.
- 1 April 2005
- Published by Wiley in Clinical Cardiology
- Vol. 28 (4) , 197-201
Open AccessStudy on changes of heme oxygenase‐1 expression in patients with coronary heart disease
Background: Heme oxygenase (HO) is a rate‐limiting enzyme of endogenetic carbon monoxide (CO) that degrades heme into carbon monoxide, bilirubin, and iron. These products have important physiologic effects: bilirubin is a potent antioxidant that can act against ischemia/reperfusion injury; there is a negative correlation between the content of HO‐1 and the incidence of coronary heart disease (CHD). Hypothesis: This study was undertaken to investigate the changes of HO‐1 in patients with CHD. Methods: Thirty‐five patients with acute myocardial infarction (AMI), 40 patients with unstable angina pectoris (UAP, diagnosed by coronary angiography), and 30 patients with stable angina pectoris (AP, diagnosed by coronary angiography) were selected for the study; another 30 patients with normal coronary artery (diagnosed by coronary angiography) were selected as controls. The levels of HO‐1 protein expression in monocyte and lymphocyte in the subjects were tested by immunohistochemistry and western blot. Computer picture analyzing systems were also used to measure the levels of HO‐1 protein expression. Results: Heme oxygenase‐1 protein is located in cell plasma. The levels of HO‐1 protein expression in patients with CHD were significantly higher than in those without CHD (pConclusions: There is a higher expression of HO‐1 in patients with CHD. The levels of HO‐1 protein are associated with the severity of CHD.